Skip to main content

Liver Diseases

The Liver Diseases group is a referent at the local, national and international level in research, and is one of the most active groups in clinical research at VHIR. The group's prominent involvement in clinical trials is a clear indication of our professionals' commitment to ensuring that patients have access to state-of-the-art therapies. Our participation and collaboration in international projects and consortiums are also a fundamental characteristic of the group. The main objective of the group is to become one of the best translational research groups in liver diseases. It is essential to be able to apply all the findings of basic research to clinical research to improve the health of patients with liver disease.

Publications

Cost-effectiveness analysis of an active search to retrieve HCV patients lost to follow-up (RELINK-C strategy) and the impact of COVID-19.

PMID: 35555847
Journal: JOURNAL OF VIRAL HEPATITIS
Year: 2022
Reference: J Viral Hepat. 2022 Jul;29(7):579-583. doi: 10.1111/jvh.13686. Epub 2022 May 23.
Impact factor: 3.728
Publication type: Paper in international publication
Authors: Vargas-Accarino, Elena, Martinez-Camprecios, Joan, Dominguez-Hernandez, Raquel, Rando-Segura, Ariadna, Riveiro-Barciela, Mar, Rodriguez-Frias, Francisco, Barreira, Ana, Palom, Adriana, Casado, Miguel Angel, Esteban, Rafael et al.
DOI: 10.1111/jvh.13686

Retreatment with Checkpoint inhibitors after a severe immune-related hepatitis: Results from a prospective multicenter study.

PMID: 35487453
Journal: Clinical Gastroenterology and Hepatology
Year: 2022
Reference: Clin Gastroenterol Hepatol. 2022 Apr 26. pii: S1542-3565(22)00403-7. doi: 10.1016/j.cgh.2022.03.050.
Impact factor: 11.382
Publication type: Paper in international publication
Authors: Riveiro-Barciela, Mar, Barreira-Diaz, Ana, Callejo-Perez, Ana, Munoz-Couselo, Eva, Diaz-Mejia, Nely, Diaz-Gonzalez, Alvaro, Londono, Maria-Carlota, Salcedo, Maria-Teresa, Buti, Maria et al.
DOI: 10.1016/j.cgh.2022.03.050

Soluble Angiotensin-Converting Enzyme 2 as a Prognostic Biomarker for Disease Progression in Patients Infected with SARS-CoV-2.

PMID: 35453934
Journal: Diagnostics
Year: 2022
Reference: Diagnostics (Basel). 2022 Apr 1;12(4). pii: diagnostics12040886. doi: 10.3390/diagnostics12040886.
Impact factor: 3.706
Publication type: Paper in international publication
Authors: Gabriel-Medina, Pablo, Diaz-Troyano, Noelia, Barquin-DelPino, Raquel, Castillo-Ribelles, Laura, Esteban, Angels, Hernandez-Gonzalez, Manuel, Ferrer-Costa, Roser, Pumarola, Tomas, Rodriguez-Frias, Francisco, Klammer, Martin et al.
DOI: 10.3390/diagnostics12040886

Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis.

PMID: 34964311
Journal: Hepatology Communications
Year: 2022
Reference: Hepatol Commun. 2022 May;6(5):1100-1112. doi: 10.1002/hep4.1881. Epub 2021 Dec 28.
Impact factor: 5.073
Publication type: Paper in international publication
Authors: Esnault, V, Pose, Elisa, Sola, Elsa, Lozano, Juan J, Juanola, Adria, Sidorova, Julia, Zaccherini, Giacomo, Giovo, I, Roux, O, Simon-Talero, M et al.
DOI: 10.1002/hep4.1881

Blog

News

The consensus establishes recommendations that could correct the current disparities related to muscle mass, weight and height and would allow for more precise prioritization of patients who require transplants more urgently.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Estudi sobre els patrons de consum habitual de l'alcohol en població jove

Des de Vall d'Hebron estem buscant 200 persones voluntàries sanes d'entre 18 i 30 anys per a participar en un estudi sobre els patrons de consum habitual de l'alcohol en població jove, en el marc del projecte StopALD.

Més informació